AMAG receives US FDA complete response for lead candidate
This article was originally published in Scrip
Executive Summary
AMAG Pharmaceuticals has received a complete response letter from the US FDAfor its NDA on ferumoxytol, an intravenous iron replacement agent, for the treatment of iron deficiency anaemia in chronic kidney disease patients, which it submitted in December 2007.